Previous 10 | Next 10 |
BERKELEY HEIGHTS, N.J. , Nov. 02, 2022 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening conditions and diseases, today announced that it w...
BERKELEY HEIGHTS, N.J., Oct. 20, 2022 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening conditions and diseases, today announced that an abstract h...
BERKELEY HEIGHTS, N.J., Sept. 07, 2022 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory disease, today announced that management will b...
CorMedix Inc. (CRMD) Q2 2022 Earnings Conference Call August 11, 2022 08:30 ET Company Participants Daniel Ferry - LifeSci Advisors, LLC Erin Mistry - Senior Vice President and Head, Payer Strategy, Government Affairs and Trade Joseph Todisco - Chief Executive Of...
Image source: The Motley Fool. CorMedix Inc Common Stock (NASDAQ: CRMD) Q2 2022 Earnings Call Aug 11, 2022 , 8:30 a.m. ET Operator Continue reading For further details see: CorMedix Inc Common Stock (CRMD) Q2 2022 Earnings Call Transcript...
CorMedix press release ( NASDAQ: CRMD ): Q2 GAAP EPS of -$0.19 beats by $0.02 . Revenue of $0.02M (+100.0% Y/Y). Joe Todisco, CorMedix CEO, commented, “While I am disappointed that we will not receive FDA approval on our PDUFA date, I remain confident in our...
BERKELEY HEIGHTS, N.J., Aug. 11, 2022 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory disease, today announced financial results for t...
Major earnings expected before the bell on Thursday include: Arrival ( ARVL ) Brookfield Asset Management ( BAM ) Cardinal Health ( CAH ) Hanesbrands ( HBI ) Himax Technologies ( HIMX ) For further details see: Notable earnings before Thur...
Biotech stocks are notoriously volatile, and reinforcing this on Tuesday was the performance of the clinical-stage company CorMedix (NASDAQ: CRMD) . A key pipeline product was again rejected by a top regulator, and as a result the shares were in free fall. They closed the day down m...
Gainers: BBQ Holdings ( BBQ ) +46% . Verona Pharma ( VRNA ) +41% . Mersana Therapeutics ( MRSN ) +31% . SAI.TECH Global ( SAI ) +30% . Atara Biotherapeutics ( ATRA ) +28% . PubMatic ( PUBM ) +24% . RumbleON ( RM...
News, Short Squeeze, Breakout and More Instantly...
2024-07-11 12:00:00 ET July 11, 2024 (Investorideas.com Newswire) Investorideas.com , a go-to investing platform releases the second of a two-part series looking at recent news and developments in the blood infections treatment market, featuring Citius Pharmaceuticals, Inc. ( Nasdaq:C...
BERKELEY HEIGHTS, N.J., July 03, 2024 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing therapeutic products for life-threatening diseases and conditions, today announced that it has commenced commercialization of DefenCath ® (tauroli...
BERKELEY HEIGHTS, N.J., June 18, 2024 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions, today announced that the U.S. Food and Drug Administration (FDA) has...